Another promising treatment for Alzheimer's has failed to provide any evidence that it reduces cognitive decline and preserves functional abilities in patients with mild to moderate Alzheimer's disease.
+Alzheimer's Reading Room
Another Phase 3 clinical trial for the purpose of finding a treatment for Alzheimer's has failed and ended.
Intravenous immunoglobulin (IVIG) failed to stop Alzheimer's in patients with mild to moderate Alzheimer's disease.
This is just another round of dissapointing and disconcerting news for the entire Alzheimer's community worldwide.
According to the World Health Organization (WHO) someone is diagnosed with dementia every four seconds worldwide.
The number one selling drug for the treatment of Alzheimer's, Namenda (memantine), was approved by the FDA in 2003. And, other than Aricept 23mg, every single phase three clinical trial for the treatment of Alzheimer's has failed since that time.
Memantine was first synthesized and patented by Eli Lilly and Company in 1968 and then developed by Merz in collaboration with Neurobiological Technologies, Inc. and Children's Hospital, and then licensed to Forest Laboratories, Inc. (NYSE: FRX) for the U.S. and Lundbeck for selected European and international markets.
I lost track, but at least 15 Alzheimer's clinical trials have failed since 2004 when Namenda first became available for purchase.